Loading
Novavax, Inc. is a biotechnology firm dedicated to discovering, developing, and commercializing vaccines aimed at preventing serious infectious diseases and addressing critical health needs. The company's diverse pipeline includes NVX-CoV2373, a coronavirus vaccine candidate currently undergoing two Phase III trials, one Phase IIb, and one Phase I/II trial. Also featured is NanoFlu, a nanoparticle-based seasonal quadrivalent influenza vaccine in Phase 3 clinical trials. Furthermore, Novavax is advancing ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine, which is in Phase II clinical trials for adults aged 60 and older, and in Phase I for pediatric use. The company holds a collaboration agreement with Takeda Pharmaceutical Company Limited for the development, manufacturing, and commercialization of its COVID-19 vaccine candidate, NVX-CoV2373. Established in 1987, Novavax, Inc. is headquartered in Gaithersburg, Maryland.
Latest quote
$10.22
−$0.12 · -1.16%
Regular session · ET · Market data may be delayed.
Novavax, Inc. is a biotechnology firm dedicated to discovering, developing, and commercializing vaccines aimed at preventing serious infectious diseases and addressing critical health needs. The company's diverse pipeline includes NVX-CoV2373, a coronavirus vaccine candidate currently undergoing two Phase III trials, one Phase IIb, and one Phase I/II trial. Also featured is NanoFlu, a nanoparticle-based seasonal quadrivalent influenza vaccine in Phase 3 clinical trials. Furthermore, Novavax is advancing ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine, which is in Phase II clinical trials for adults aged 60 and older, and in Phase I for pediatric use. The company holds a collaboration agreement with Takeda Pharmaceutical Company Limited for the development, manufacturing, and commercialization of its COVID-19 vaccine candidate, NVX-CoV2373. Established in 1987, Novavax, Inc. is headquartered in Gaithersburg, Maryland.
Regular session · ET · Market data may be delayed.
AI-powered factor overview
GoAI Score
Hold
Wait — insufficient conviction to act
Valuation
82
Deep Value
Sentiment
56
Mixed
Risk
64
High Risk
Momentum
57
Neutral
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Novavax, Inc. is a biotechnology firm dedicated to discovering, developing, and commercializing vaccines aimed at preventing serious infectious diseases and addressing critical health needs. The company's diverse pipeline includes NVX-CoV2373, a coronavirus vaccine candidate currently undergoing two Phase III trials, one Phase IIb, and one Phase I/II trial. Also featured is NanoFlu, a nanoparticle-based seasonal quadrivalent influenza vaccine in Phase 3 clinical trials. Furthermore, Novavax is advancing ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine, which is in Phase II clinical trials for adults aged 60 and older, and in Phase I for pediatric use. The company holds a collaboration agreement with Takeda Pharmaceutical Company Limited for the development, manufacturing, and commercialization of its COVID-19 vaccine candidate, NVX-CoV2373. Established in 1987, Novavax, Inc. is headquartered in Gaithersburg, Maryland.
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 1.12B USD | 682.16M USD | 556.38M USD | 1.6B USD | 197.58M USD |
| Cost of goods sold | 71.14M USD | 202.74M USD | 343.77M USD | 902.64M USD | — |
| Gross profit | 1.05B USD | 479.42M USD | 212.61M USD | 696.31M USD | 197.58M USD |
| Research and development | 336.82M USD | 391.17M USD | 737.5M USD | 1.24B USD | 2.53B USD |
| Selling, general, and administrative | 150.35M USD | 337.19M USD | 468.95M USD | 488.69M USD | 298.36M USD |
| Operating expenses | 489.07M USD | 728.35M USD | 779.13M USD | 1.34B USD | 1.88B USD |
| Interest expense | 22.55M USD | 20.08M USD | 14.42M USD | 19.88M USD | 21.13M USD |
| Depreciation and amortization | 27.61M USD | 48.5M USD | 41.23M USD | 29.05M USD | 12.66M USD |
| Operating income | 563.27M USD | −248.93M USD | −566.51M USD | −644.74M USD | −1.69B USD |
| Net income | 440.3M USD | −187.5M USD | −545.06M USD | −657.94M USD | −1.74B USD |
Company facts updated Sep 6, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Funds reporting this stock among their holdings, ordered by reported position size.
State Street SPDR S&P Biotech ETFXBI82.79M0.72%11.49B USD0.35%$163.81-0.35%
iShares Russell 2000 ETFIWM39.33M0.05%79.88B USD0.19%$296.01+0.28%
Vanguard Morningstar Total Stock Market ETFVTI38.04M0.00%2.3T USD0.03%$379.73-0.32%
Vanguard Morningstar Small-Cap ETFVB27.72M0.01%183.4B USD0.03%$300.01+0.05%
Vanguard Morningstar Small-Cap Growth ETFVBK15.99M0.04%43.8B USD0.05%$349.44+0.01%
iShares Russell 2000 Value ETFIWN14.54M0.10%14.47B USD0.24%$224.62+0.40%
Vanguard Extended Market ETFVXF13.88M0.01%93.7B USD0.05%$242.66+0.14%
Invesco Biotechnology & Genome ETFPBE12.65M2.98%423.74M USD0.59%$97.79-0.94%State Street SPDR S&P Biotech ETFXBIiShares Russell 2000 ETFIWMVanguard Morningstar Total Stock Market ETFVTIVanguard Morningstar Small-Cap ETFVBVanguard Morningstar Small-Cap Growth ETFVBKiShares Russell 2000 Value ETFIWNVanguard Extended Market ETFVXFInvesco Biotechnology & Genome ETFPBEAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
